Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Adenosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 known ✓ | P0DMS8 | 4/20 | 0.81 |
| ▸ | ADORA2A known ✓ | P29274 | 1/20 | 0.81 |
| ▸ | ADORA2B known ✓ | P29275 | 1/20 | 0.81 |
| ▸ | ADORA1 known ✓ | P30542 | 1/20 | 0.81 |
| ▸ | DOT1L | Q8TEK3 | 2/20 | 0.81 |
| ▸ | DPP4 | P27487 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.81 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.81 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.81 |
| ▸ | GAPDH | P04406 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | STAT6 | P42226 | 1/20 | 0.81 |
| ▸ | PI4KA | P42356 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.81 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.81 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.81 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vidarabine SCHEMBL27371675 | 1.00 | ADORA3 (0.81) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| Inosine SCHEMBL21840403 | 0.94 | ADORA3 (0.72) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL23201584 | 0.92 | ADORA3 (0.68) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| Vidarabine SCHEMBL27261659 | 0.92 | ADORA3 (0.71) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| Vidarabine SCHEMBL27261788 | 0.91 | ADORA3 (0.70) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL23804425 | 0.90 | ADORA3 (1.00) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL1821276 | 0.90 | ADORA3 (1.00) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL24538665 | 0.90 | ADORA3 (1.00) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL2228590 | 0.90 | ADORA3 (1.00) | ADORA3DOT1LDPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL406207 | 0.90 | ADORA3 (1.00) | ADORA3DOT1LDPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118058376-A | Two-way solid-state fermentation ginseng sweet potato preserved fruit with ganoderma lucidum and preparation method thereof | 吉林省养易多科技有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-11905308-B2 | Nucleic acid compound and oligonucleotide | OSAKA UNIVERSITY (JP) | 2024-02-20 | — | — | US | disclosed |
| CN-115521245-B | Alkaloid compound in purslane, and extraction and separation method and application thereof | 辽宁中医药大学 | 2024-01-19 | — | — | CN | disclosed |
| CN-113698446-B | Alkaloid compound in purslane and extraction and separation method thereof | 辽宁中医药大学 | 2023-05-16 | — | — | CN | disclosed |
| CN-114213473-B | Three alkaloid compounds in purslane and extraction and separation method thereof | 辽宁中医药大学 | 2023-04-25 | — | — | CN | disclosed |
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | LIGAND UK DEVELOPMENT LIMITED (GB) | 2023-03-30 | — | — | US | disclosed |
| CN-115521245-A | Alkaloid compound in purslane and extraction and separation method and application thereof | 辽宁中医药大学 | 2022-12-27 | — | — | CN | disclosed |
| US-20220169671-A1 | NUCLEIC ACID COMPOUND AND OLIGONUCLEOTIDE | OSAKA UNIVERSITY (JP) | 2022-06-02 | — | — | US | disclosed |
| CN-113264828-B | Benzoic acid compound in purslane and extraction and separation method thereof | 辽宁中医药大学 | 2022-05-17 | — | — | CN | disclosed |
| CN-114213473-A | Three alkaloid compounds in purslane and extraction and separation method thereof | 辽宁中医药大学 | 2022-03-22 | — | — | CN | disclosed |
| US-6197788-B1 | (−)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders | VERNALIS RESEARCH LIMITED (GB) | 2001-03-06 | — | — | US | disclosed |
| WO-2001002409-A1 | THIENO- AND FUROPYRIMIDINE DERIVATIVES AS A2A-RECEPTOR ANTAGONISTS | VERNALIS RESEARCH LIMITED (GB) | 2001-01-11 | — | — | WO | disclosed |
| WO-2000013682-A2 | 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS.(II) | VERNALIS RESEARCH LIMITED (GB) | 2000-03-16 | — | — | WO | disclosed |
| WO-2000013681-A2 | 4-QUINOLINEMETHANOL DERIVATIVES AS PURINE RECEPTOR ANTAGONISTS (I) | VERNALIS RESEARCH LIMITED (GB) | 2000-03-16 | — | — | WO | disclosed |
| EP-0975345-A1 | (-)-MEFLOQUINE TO BLOCK PURINERGIC RECEPTORS AND TO TREAT MOVEMENT OR NEURODEGENERATIVE DISORDERS | Cerebrus Pharmaceuticals Limited (GB) | 2000-02-02 | — | — | EP | disclosed |
| WO-1999026627-A1 | (-)-MEFLOQUINE TO BLOCK PURINERGIC RECEPTORS AND TO TREAT MOVEMENT OR NEURODEGENERATIVE DISORDERS | CEREBRUS LIMITED (GB) | 1999-06-03 | — | — | WO | disclosed |
| EP-0420977-A4 | NOVEL LYOPHILIZED AND RECONSTITUTED RED BLOOD CELL COMPOSITIONS | — | 1991-11-06 | — | — | EP | disclosed |
| EP-0420977-A1 | NOVEL LYOPHILIZED AND RECONSTITUTED RED BLOOD CELL COMPOSITIONS | CRYOPHARM CORPORATION (US) | 1991-04-10 | — | — | EP | disclosed |
| WO-1990012582-A1 | NOVEL LYOPHILIZED AND RECONSTITUTED RED BLOOD CELL COMPOSITIONS | CRYOPHARM CORPORATION (US) | 1990-11-01 | — | — | WO | disclosed |
| US-4354913-A | MEMBRANE HAVING SURFACE CONTAINING THE REACTION PRODUCT OF GLUTARALDEHYDE AND THE ENZYME | RADELKIS ELEKTROKEMIAI MUSZERGYARTO SZOVETKEZET (HU) | 1982-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11905308-B2 | Nucleic acid compound and oligonucleotide | NSUN2, NUDT1, EFTUD2 | ADORA3 348/4885ADORA2A 493/4885ADORA2B 565/4885 |
| US-20220169671-A1 | NUCLEIC ACID COMPOUND AND OLIGONUCLEOTIDE | NSUN2, NUDT1, EFTUD2 | ADORA3 348/4885ADORA2A 493/4885ADORA2B 565/4885 |
| US-20230100842-A1 | TRIAZOLO[4,5-D] PYRAMIDINE DERIVATIVES AND THEIR USE AS PURINE RECEPTOR ANTAGONISTS | P2RX5, P2RY1, P2RX3 | ADORA3 14/4885ADORA2A 11/4885ADORA2B 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.